These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

949 related articles for article (PubMed ID: 24613036)

  • 1. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
    Brechbiel J; Miller-Moslin K; Adjei AA
    Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
    Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
    Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
    Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
    Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
    McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
    J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
    Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
    Asati V; Mahapatra DK; Bharti SK
    Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hedgehog inhibitor sonidegib potentiates
    Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
    BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
    Bertrand FE; Steelman LS; Chappell WH; Abrams SL; Shelton JG; White ER; Ludwig DL; McCubrey JA
    Leukemia; 2006 Jul; 20(7):1254-60. PubMed ID: 16642049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
    Wolin EM
    Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathways: BCR-ABL.
    Cilloni D; Saglio G
    Clin Cancer Res; 2012 Feb; 18(4):930-7. PubMed ID: 22156549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitogen-activated protein kinases and Hedgehog-GLI signaling in cancer: A crosstalk providing therapeutic opportunities?
    Rovida E; Stecca B
    Semin Cancer Biol; 2015 Dec; 35():154-67. PubMed ID: 26292171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells.
    Justilien V; Fields AP
    Clin Cancer Res; 2015 Feb; 21(3):505-13. PubMed ID: 25646180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
    Slomovitz BM; Coleman RL
    Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
    Markova B; Albers C; Breitenbuecher F; Melo JV; Brümmendorf TH; Heidel F; Lipka D; Duyster J; Huber C; Fischer T
    Oncogene; 2010 Feb; 29(5):739-51. PubMed ID: 19881535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-signaling among phosphinositide-3 kinase, mitogen-activated protein kinase and sonic hedgehog pathways exists in esophageal cancer.
    Wei L; Xu Z
    Int J Cancer; 2011 Jul; 129(2):275-84. PubMed ID: 20839260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
    Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
    Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
    Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
    Renshaw J; Taylor KR; Bishop R; Valenti M; De Haven Brandon A; Gowan S; Eccles SA; Ruddle RR; Johnson LD; Raynaud FI; Selfe JL; Thway K; Pietsch T; Pearson AD; Shipley J
    Clin Cancer Res; 2013 Nov; 19(21):5940-51. PubMed ID: 23918606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.